Recent advances in synthetic pharmacotherapies for dyslipidaemias

Cesare R. Sirtori, Shizuya Yamashita, Maria Francesca Greco, Alberto Corsini, Gerald F Watts, Massimiliano Ruscica

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and safe oral agents for addressing classical lipid targets, low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). LDL-C is unquestionably causal in the development of atherogenesis and atherosclerotic cardiovascular disease, but new options are required to address triglyceride-rich lipoproteins and lipoprotein(a). For hypercholesterolaemia, pitavastatin provides a very low dose and potent statin that does not adversely affect glucose metabolism; bempedoic acid acts at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and is not associated with muscular side effects. For hypertriglyceridaemia, pemafibrate displays a unique and selective agonist activity on peroxisomal proliferator activated receptor-α that does not elevate homocysteine or creatinine. Although omega-3 fatty acids supplementation is not effective in secondary prevention, high dose eicosapentaenoic ethyl ester can lead to a remarkable fall in first and recurrent events in high risk patients with hypertriglyceridaemia/low HDL-C. Gemcabene, a dicarboxylic acid regulating apolipoprotein B-100, is effective in reducing both cholesterol and triglycerides. Among cholesteryl ester transfer protein antagonists that elevate HDL-C, only anacetrapib reduces cardiovascular events. Probucol stimulates reverse cholesteryl ester transport, lowers LDL-C stabilizing plaques and may lower incidence of cardiovascular events. These agents, which act through novel mechanisms, afford good and potentially safe treatment choices that may increase adherence and the attainment of therapeutic targets.

Original languageEnglish
JournalEuropean Journal of Preventive Cardiology
DOIs
Publication statusE-pub ahead of print - 6 May 2019

Fingerprint

Dyslipidemias
LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypertriglyceridemia
Drug Therapy
HDL Cholesterol
Triglycerides
Probucol
Apolipoprotein B-100
Cholesterol Ester Transfer Proteins
Hydroxymethylglutaryl CoA Reductases
Dicarboxylic Acids
Lipoprotein(a)
Cholesterol Esters
Omega-3 Fatty Acids
Homocysteine
Secondary Prevention
Hypercholesterolemia
Biological Products
Lipoproteins

Cite this

Sirtori, Cesare R. ; Yamashita, Shizuya ; Francesca Greco, Maria ; Corsini, Alberto ; F Watts, Gerald ; Ruscica, Massimiliano. / Recent advances in synthetic pharmacotherapies for dyslipidaemias. In: European Journal of Preventive Cardiology. 2019.
@article{2439272446b544d6944c6ecd0f3886c9,
title = "Recent advances in synthetic pharmacotherapies for dyslipidaemias",
abstract = "Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and safe oral agents for addressing classical lipid targets, low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). LDL-C is unquestionably causal in the development of atherogenesis and atherosclerotic cardiovascular disease, but new options are required to address triglyceride-rich lipoproteins and lipoprotein(a). For hypercholesterolaemia, pitavastatin provides a very low dose and potent statin that does not adversely affect glucose metabolism; bempedoic acid acts at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and is not associated with muscular side effects. For hypertriglyceridaemia, pemafibrate displays a unique and selective agonist activity on peroxisomal proliferator activated receptor-α that does not elevate homocysteine or creatinine. Although omega-3 fatty acids supplementation is not effective in secondary prevention, high dose eicosapentaenoic ethyl ester can lead to a remarkable fall in first and recurrent events in high risk patients with hypertriglyceridaemia/low HDL-C. Gemcabene, a dicarboxylic acid regulating apolipoprotein B-100, is effective in reducing both cholesterol and triglycerides. Among cholesteryl ester transfer protein antagonists that elevate HDL-C, only anacetrapib reduces cardiovascular events. Probucol stimulates reverse cholesteryl ester transport, lowers LDL-C stabilizing plaques and may lower incidence of cardiovascular events. These agents, which act through novel mechanisms, afford good and potentially safe treatment choices that may increase adherence and the attainment of therapeutic targets.",
keywords = "bempedoic acid, gemcabene, high-dose eicosapentaenoic acid, pitavastatin, probucol",
author = "Sirtori, {Cesare R.} and Shizuya Yamashita and {Francesca Greco}, Maria and Alberto Corsini and {F Watts}, Gerald and Massimiliano Ruscica",
year = "2019",
month = "5",
day = "6",
doi = "10.1177/2047487319845314",
language = "English",
journal = "European Journal of Cardiovascular Prevention & Rehabilitation",
issn = "1350-6277",
publisher = "SAGE Publications Ltd",

}

Recent advances in synthetic pharmacotherapies for dyslipidaemias. / Sirtori, Cesare R.; Yamashita, Shizuya; Francesca Greco, Maria; Corsini, Alberto; F Watts, Gerald; Ruscica, Massimiliano.

In: European Journal of Preventive Cardiology, 06.05.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Recent advances in synthetic pharmacotherapies for dyslipidaemias

AU - Sirtori, Cesare R.

AU - Yamashita, Shizuya

AU - Francesca Greco, Maria

AU - Corsini, Alberto

AU - F Watts, Gerald

AU - Ruscica, Massimiliano

PY - 2019/5/6

Y1 - 2019/5/6

N2 - Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and safe oral agents for addressing classical lipid targets, low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). LDL-C is unquestionably causal in the development of atherogenesis and atherosclerotic cardiovascular disease, but new options are required to address triglyceride-rich lipoproteins and lipoprotein(a). For hypercholesterolaemia, pitavastatin provides a very low dose and potent statin that does not adversely affect glucose metabolism; bempedoic acid acts at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and is not associated with muscular side effects. For hypertriglyceridaemia, pemafibrate displays a unique and selective agonist activity on peroxisomal proliferator activated receptor-α that does not elevate homocysteine or creatinine. Although omega-3 fatty acids supplementation is not effective in secondary prevention, high dose eicosapentaenoic ethyl ester can lead to a remarkable fall in first and recurrent events in high risk patients with hypertriglyceridaemia/low HDL-C. Gemcabene, a dicarboxylic acid regulating apolipoprotein B-100, is effective in reducing both cholesterol and triglycerides. Among cholesteryl ester transfer protein antagonists that elevate HDL-C, only anacetrapib reduces cardiovascular events. Probucol stimulates reverse cholesteryl ester transport, lowers LDL-C stabilizing plaques and may lower incidence of cardiovascular events. These agents, which act through novel mechanisms, afford good and potentially safe treatment choices that may increase adherence and the attainment of therapeutic targets.

AB - Despite the demonstrated benefits of statins and injectable biologics, there is a need for new and safe oral agents for addressing classical lipid targets, low-density lipoprotein cholesterol (LDL-C), triglycerides and high-density lipoprotein cholesterol (HDL-C). LDL-C is unquestionably causal in the development of atherogenesis and atherosclerotic cardiovascular disease, but new options are required to address triglyceride-rich lipoproteins and lipoprotein(a). For hypercholesterolaemia, pitavastatin provides a very low dose and potent statin that does not adversely affect glucose metabolism; bempedoic acid acts at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and is not associated with muscular side effects. For hypertriglyceridaemia, pemafibrate displays a unique and selective agonist activity on peroxisomal proliferator activated receptor-α that does not elevate homocysteine or creatinine. Although omega-3 fatty acids supplementation is not effective in secondary prevention, high dose eicosapentaenoic ethyl ester can lead to a remarkable fall in first and recurrent events in high risk patients with hypertriglyceridaemia/low HDL-C. Gemcabene, a dicarboxylic acid regulating apolipoprotein B-100, is effective in reducing both cholesterol and triglycerides. Among cholesteryl ester transfer protein antagonists that elevate HDL-C, only anacetrapib reduces cardiovascular events. Probucol stimulates reverse cholesteryl ester transport, lowers LDL-C stabilizing plaques and may lower incidence of cardiovascular events. These agents, which act through novel mechanisms, afford good and potentially safe treatment choices that may increase adherence and the attainment of therapeutic targets.

KW - bempedoic acid

KW - gemcabene

KW - high-dose eicosapentaenoic acid

KW - pitavastatin

KW - probucol

UR - http://www.scopus.com/inward/record.url?scp=85065520240&partnerID=8YFLogxK

U2 - 10.1177/2047487319845314

DO - 10.1177/2047487319845314

M3 - Review article

JO - European Journal of Cardiovascular Prevention & Rehabilitation

JF - European Journal of Cardiovascular Prevention & Rehabilitation

SN - 1350-6277

ER -